000 03936nam a22004575i 4500
001 vtls000544913
003 RU-ToGU
005 20210922083153.0
007 cr nn 008mamaa
008 160915s2014 gw | s |||| 0|eng d
020 _a9783642452574
_9978-3-642-45257-4
024 7 _a10.1007/978-3-642-45257-4
_2doi
035 _ato000544913
040 _aSpringer
_cSpringer
_dRU-ToGU
050 4 _aRC434.2-574
072 7 _aMMH
_2bicssc
072 7 _aMED105000
_2bisacsh
082 0 4 _a616.89
_223
245 1 0 _aTreatment–Refractory Schizophrenia
_helectronic resource
_bA Clinical Conundrum /
_cedited by Peter F. Buckley, Fiona Gaughran.
260 _aBerlin, Heidelberg :
_bSpringer Berlin Heidelberg :
_bImprint: Springer,
_c2014.
300 _aVIII, 230 p. 7 illus., 6 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
505 0 _aDefinitions and scope of treatment-refractory schizophrenia -- Biology of schizophrenia: Is treatment-refractoriness synonymous with severity of illness -- Evolution of refractoriness -- Medical and psychiatric comorbidities: Complicating treatment expectations -- Overview of pharmacologic treatments and guidelines -- Clozapine: Gold standard treatment for refractory schizophrenia: Now or never -- Augmenting clozapine and other antipsychotic medications: Pharmacologic choices and differential outcomes -- Augmenting clozapine therapy: Emerging neuromodulatory strategies -- Cognitive remediation for refractory schizophrenia -- Psychological and familial therapies for refractory schizophrenia -- Vocational performance of patients with chronic schizophrenia -- Refractory schizophrenia and the criminal justice system: A failure of continuity of care and a real challenge -- Personalized medicine: A ‘game changer’ in the care of patients with treatment-refractory schizophrenia?
520 _aSchizophrenia is often associated with an inadequate response to pharmacological and non-pharmacological treatments. How to treat patients who have an unsatisfactory response to anti-psychotics, including clozapine - which is unequivocally the most powerful antipsychotic medication for this recalcitrant population  - remains a clinical conundrum. A range of adjunctive medications have been tried with mixed results; there has also been renewed interest in the role of neuromodulatory strategies, electroconvulsive therapy, and cognitive and vocational approaches. Perhaps a bright spot for the future lies in the evolution of pharmacogenetic approaches for individualized care.   In this book, leading experts from Europe, Australia and the Americas provide a timely appraisal of treatments for the most severely ill schizophrenia patients. This clinically focused  book is informed by the latest research on the neurobiology and treatment of schizophrenia. It is comprehensive in scope, covering current treatment options, various add-on approaches, and a range of psychosocial treatments. The contributors are respected experts who have combined their clinical experience with cutting-edge research to provide readers with authoritative information on fundamental aspects of clinical care for schizophrenia.
650 0 _amedicine.
_9566220
650 0 _aPsychiatry.
_9566321
650 0 _aPsychology, clinical.
_9265970
650 1 4 _aMedicine & Public Health.
_9566221
650 2 4 _aPsychiatry.
_9566321
650 2 4 _aClinical Psychology.
_9265974
700 1 _aBuckley, Peter F.
_eeditor.
_9452912
700 1 _aGaughran, Fiona.
_eeditor.
_9452913
710 2 _aSpringerLink (Online service)
_9143950
773 0 _tSpringer eBooks
856 4 0 _uhttp://dx.doi.org/10.1007/978-3-642-45257-4
912 _aZDB-2-SME
999 _c402700